What sermorelin is and how it works
Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) — the 29 N-terminal amino acids of the naturally occurring 44-amino-acid GHRH. It works by binding to the GHRH receptor on the somatotroph cells of the anterior pituitary gland, stimulating them to produce and release growth hormone (GH) in pulses that mirror the body’s natural secretory pattern.
This mechanism is fundamentally different from synthetic GH (somatropin). Synthetic GH bypasses the pituitary entirely and delivers GH exogenously. Sermorelin asks the pituitary to do the secreting — which means the feedback mechanisms (including somatostatin inhibition) remain intact. Clinicians often describe this as a more “physiologic” approach because the body’s own regulatory architecture stays engaged.
Why can’t sermorelin be taken as a pill?
Sermorelin is a 29-amino-acid peptide. That size and chemical character create three overlapping barriers to oral absorption:
1. Proteolytic degradation
The GI tract is designed to break down peptides — that is a feature, not a bug, of digestive physiology. Proteolytic enzymes (pepsin in the stomach, trypsin and chymotrypsin in the small intestine) are highly efficient at cleaving peptide bonds. A 29-amino-acid peptide like sermorelin is an efficient substrate for these enzymes. Most of the intact peptide is degraded before it can reach the intestinal epithelium for absorption.
2. Low membrane permeability
Even if sermorelin survived the proteolytic environment intact, its molecular size and hydrophilicity create a second barrier: the intestinal epithelial membrane is poorly permeable to large hydrophilic molecules. Passive transcellular diffusion, the primary route for most small-molecule drug absorption, is essentially closed to peptides of this size.
3. Hepatic first-pass metabolism
Any sermorelin that did cross the intestinal epithelium would then enter the portal circulation and pass through the liver before reaching systemic circulation. The liver efficiently metabolizes peptides, creating a third reduction in bioavailable drug.
The combined effect of these three barriers is that oral bioavailability for peptides of sermorelin’s size is typically less than 1-2% without specialized formulation technology. This is why oral peptide delivery is an active area of pharmaceutical research — it is genuinely difficult, not a solved problem.
A swallowed sermorelin pill is mostly digested before it ever reaches your bloodstream — which is why the route, not the molecule, decides whether it works.
What about sublingual and intranasal sermorelin?
The sublingual mucosa (under the tongue) and nasal mucosa bypass the proteolytic environment of the stomach and avoid first-pass hepatic metabolism, which is why these routes have attracted interest for peptide delivery. Both offer direct access to capillary beds with lower enzymatic activity than the GI tract.
Intranasal sermorelin has been studied in the literature — early work including the Rosenfeld group examined subcutaneous versus intranasal administration and compared the resulting GH pulsatility profiles. Intranasal delivery can produce a measurable GH response, though typically with lower and more variable bioavailability than subcutaneous injection.
Sublingual compounded sermorelin preparations exist in the compounding pharmacy market, but controlled comparative pharmacokinetic data versus subcutaneous injection is limited. The mucosa does present some absorption opportunity, but peptide stability in the oral environment and absorption efficiency across the sublingual mucosa are still significant limitations relative to injection.
Subcutaneous injection remains the standard because it provides the most consistent, well-characterized bioavailability. The drug reaches systemic circulation through local capillary and lymphatic networks without the enzymatic gauntlet of the GI tract.
OTC sermorelin supplements: a different category entirely
A number of over-the-counter products are marketed as “sermorelin supplements” or “sermorelin pills.” These are categorically different from prescription compounded sermorelin:
- They do not contain prescription sermorelin. Sermorelin is a prescription medication. OTC products cannot legally contain it as an active ingredient in an effective dose.
- They typically contain amino acid precursors or secretagogue-adjacent ingredients, not the actual peptide. The labeling may be designed to imply a connection to the clinically studied compound without containing it.
- They are unregulated as dietary supplements. FDA dietary supplement oversight is substantially lighter than pharmaceutical oversight. Purity, potency, and efficacy claims are not verified pre-market.
If you are researching sermorelin for growth hormone support, the distinction between an OTC supplement marketed with “sermorelin” in the name and a clinician-prescribed compounded sermorelin preparation is not cosmetic. They are different products with different regulatory status and different clinical evidence.
How do clinicians actually prescribe sermorelin?
In current clinical practice, compounded sermorelin is prescribed as a subcutaneous injection, typically administered nightly before sleep. The timing is deliberate: growth hormone secretion is heavily concentrated during slow-wave sleep, and administering a GHRH receptor agonist before sleep aligns the stimulus with the body’s natural secretory window.
Dosing is individualized by the prescribing clinician based on the patient’s age, weight, IGF-1 levels (IGF-1 is the downstream mediator of GH’s anabolic effects and a more stable marker than GH itself), and clinical goals. Protocols typically include a titration period and baseline labs before initiation.
Sermorelin is compounded in the USA by licensed 503A pharmacies and is not FDA-approved as a drug. It was previously available as the FDA-approved product Geref, which was withdrawn from the market; compounded sermorelin is a separate preparation available under a valid clinician prescription.
Frequently asked questions
Do sermorelin pills exist?
Compounding pharmacies do prepare some oral or sublingual sermorelin formulations, but these face a fundamental bioavailability problem: sermorelin is a 29-amino-acid peptide that is rapidly degraded by GI proteases. Oral bioavailability of peptides of this size is typically very low without specialized delivery systems. Subcutaneous injection is the standard clinically used route.
Is sermorelin effective as an oral supplement?
Over-the-counter sermorelin "supplements" or capsules are not the same as prescription compounded sermorelin. No OTC product contains active prescription sermorelin in a bioavailable form. These products should not be confused with clinician-prescribed compounded sermorelin.
How is sermorelin typically administered?
Clinician-prescribed compounded sermorelin is administered via subcutaneous injection, typically nightly before sleep to align with the body's natural growth hormone pulse. Some protocols use intranasal administration, which has also been studied, though the subcutaneous route has the most established pharmacokinetic data.
Is sermorelin FDA-approved?
Sermorelin (as Geref) was formerly FDA-approved for growth hormone deficiency in children but was withdrawn from the market. It is now available as a compounded preparation from licensed 503A pharmacies in the USA, prescribed by licensed clinicians for off-label use in adults. Compounded sermorelin is not FDA-approved.
Why does timing matter for sermorelin injections?
Growth hormone is secreted in pulses, with the largest pulse occurring during slow-wave sleep. Sermorelin stimulates the pituitary to release growth hormone through the GHRH receptor. Administering it before sleep aligns the drug's action with the natural sleep-associated pulse, which is the basis for the standard nightly dosing schedule.